Literature DB >> 11918075

High-affinity interactions of ligands at recombinant guinea pig 5HT7 receptors.

R E Wilcox1, J E Ragan, R S Pearlman, M Y Brusniak, R M Eglen, D W Bonhaus, T E Tenner, J D Miller.   

Abstract

The serotonin 5HT7 receptor has been implicated in numerous physiological and pathological processes from circadian rhythms to depression and schizophrenia. Clonal cell lines heterologously expressing recombinant receptors offer good models for understanding drug-receptor interactions and development of quantitative structure-activity relationships (QSAR). Comparative Molecular Field Analysis (CoMFA) is an important modern QSAR procedure that relates the steric and electrostatic fields of a set of aligned compounds to affinity. Here, we utilized CoMFA to predict affinity for a number of high-affinity ligands at the recombinant guinea pig 5HT7 receptor. Using R-lisuride as the template, a final CoMFA model was derived using procedures similar to those of our recent papers. The final cross-validated model accounted for >85% of the variance in the compound affinity data, while the final non-cross validated model accounted for >99% of the variance. Model evaluation was done using cross-validation methods with groups of 5 ligands. Twenty cross-validation runs yielded an average predictive r2(q2) of 0.779 +/- 0.015 (range: 0.669-0.867). Furthermore, 3D-chemical database search queries derived from the model yielded hit lists of promising agents with high structural similarity to the template. Together, these results suggest a possible basis for high-affinity drug action at 5HT7 receptors.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11918075     DOI: 10.1023/a:1014319812972

Source DB:  PubMed          Journal:  J Comput Aided Mol Des        ISSN: 0920-654X            Impact factor:   3.686


  32 in total

1.  A novel, potent, and selective 5-HT(7) antagonist: (R)-3-(2-(2-(4-methylpiperidin-1-yl)ethyl)pyrrolidine-1-sulfonyl) phen ol (SB-269970).

Authors:  P J Lovell; S M Bromidge; S Dabbs; D M Duckworth; I T Forbes; A J Jennings; F D King; D N Middlemiss; S K Rahman; D V Saunders; L L Collin; J J Hagan; G J Riley; D R Thomas
Journal:  J Med Chem       Date:  2000-02-10       Impact factor: 7.446

Review 2.  Adenylate cyclase assay.

Authors:  Y Salomon
Journal:  Adv Cyclic Nucleotide Res       Date:  1979

3.  Evidence for 5-HT7 receptors mediating relaxation of human colonic circular smooth muscle.

Authors:  N H Prins; M R Briejer; P J Van Bergen; L M Akkermans; J A Schuurkes
Journal:  Br J Pharmacol       Date:  1999-10       Impact factor: 8.739

4.  Cloning, expression and pharmacology of a truncated splice variant of the human 5-HT7 receptor (h5-HT7b).

Authors:  J R Jasper; A Kosaka; Z P To; D J Chang; R M Eglen
Journal:  Br J Pharmacol       Date:  1997-09       Impact factor: 8.739

Review 5.  The 5-HT7 receptor: orphan found.

Authors:  R M Eglen; J R Jasper; D J Chang; G R Martin
Journal:  Trends Pharmacol Sci       Date:  1997-04       Impact factor: 14.819

6.  Substructural analysis. A novel approach to the problem of drug design.

Authors:  R D Cramer; G Redl; C E Berkoff
Journal:  J Med Chem       Date:  1974-05       Impact factor: 7.446

7.  CoMFA-based prediction of agonist affinities at recombinant wild type versus serine to alanine point mutated D2 dopamine receptors.

Authors:  R E Wilcox; W H Huang; M Y Brusniak; D M Wilcox; R S Pearlman; M M Teeter; C J DuRand; B L Wiens; K A Neve
Journal:  J Med Chem       Date:  2000-08-10       Impact factor: 7.446

8.  A model of the serotonin 5-HT1A receptor: agonist and antagonist binding sites.

Authors:  W Kuipers; I Van Wijngaarden; A P Ijzerman
Journal:  Drug Des Discov       Date:  1994-04

9.  Application of quantitative structure-activity relationships in the development of the antiallergic pyranenamines.

Authors:  R D Cramer; K M Snader; C R Willis; L W Chakrin; J Thomas; B M Sutton
Journal:  J Med Chem       Date:  1979-06       Impact factor: 7.446

Review 10.  International Union of Pharmacology classification of receptors for 5-hydroxytryptamine (Serotonin).

Authors:  D Hoyer; D E Clarke; J R Fozard; P R Hartig; G R Martin; E J Mylecharane; P R Saxena; P P Humphrey
Journal:  Pharmacol Rev       Date:  1994-06       Impact factor: 25.468

View more
  1 in total

1.  Phe369(7.38) at human 5-HT(7) receptors confers interspecies selectivity to antagonists and partial agonists.

Authors:  Thibault Varin; Hugo Gutiérrez-de-Terán; Marián Castro; José Brea; Frederic Fabis; François Dauphin; Johan Aqvist; Alban Lepailleur; Pilar Perez; Javier Burgueño; José Miguel Vela; Maria Isabel Loza; Jordi Rodrigo
Journal:  Br J Pharmacol       Date:  2009-11-18       Impact factor: 8.739

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.